Trial Profile
Open Label, Randomized Multicentre Phase II/III Study of Docetaxel in Combination With Cisplatin (CDDP) or Docetaxel in Combination With 5-Fluorouracil (5-FU) and CDDP Compared to the Combination of CDDP and 5-FU in Patients With Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 27 Feb 2020
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cisplatin; Fluorouracil
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 25 Jan 2020 Results assessing the patterns of opioid use, and evaluating the impact of opioid use on survival outcomes among patients with advanced GI cancers who were included in eight clinical trials (NCT01124786; NCT00844649; NCT00290966; NCT00678535; NCT00699374; NCT00272051; NCT00305188; NCT00384176) presented at the 2020 Gastrointestinal Cancers Symposium
- 01 Aug 2007 Results have been published.
- 01 Nov 2006 Primary endpoint 'Time to disease progression' has been met.